Dose Insider / FDA warning letters / Matthew Stern, CEO MyStart Health LLC.

Matthew Stern, CEO MyStart Health LLC.FDA warning letter, September 9, 2025

FDA letter of September 9, 2025 · posted September 16, 2025 · checked against fda.gov on November 20, 2026

On September 9, 2025, FDA sent Matthew Stern, CEO MyStart Health LLC. of Newark, DE, a warning letter saying that claims on mystarthealth.com about compounded semaglutide were false or misleading. FDA reviewed the website in August 2025.

4 sectionsof the Food, Drug, and Cosmetic Act cited in the letter
FDA letters on GLP-1 drugs, by yearAll 164 letters in this database; the year of this one in coral202322024112025, this letter73202678FDA letters on GLP-1 drugs,by yearAll 164 letters in this database; the year of thisone in coral202322024112025, this letter73202678

70 letters are of the same kind as this one: websites selling drugs that FDA considers unapproved and misbranded.

On this page

FDA posted the letter on September 16, 2025. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1

What does the letter say, in brief?

CompanyMatthew Stern, CEO MyStart Health LLC.
LocationNewark, DE
Website namedmystarthealth.com
Letter datedSeptember 9, 2025
Posted by FDASeptember 16, 2025
Issuing officeCenter for Drug Evaluation and Research (CDER)
FDA’s subject lineUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
Drugs namedsemaglutide
Kind of letterUnapproved drugs sold online
Reply asked withinfifteen (15) working days
Close-out letterNone posted as of November 20, 2026
FDA recordMARCS-CMS 714755

What did FDA quote from mystarthealth.com?

The letter quotes 1 passage. FDA quotes them as examples and says in most letters that the list is not exhaustive.1

Which parts of the law did FDA cite?

The letter cites 4 sections of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.

SectionWhat it saysLetters citing it
502(a)A drug is misbranded if its labeling is false or misleading117
502(bb)A compounded drug is misbranded if its advertising or promotion is false or misleading111
301(a)It is prohibited to introduce an adulterated or misbranded drug into interstate commerce142
301(c)It is prohibited to receive an adulterated or misbranded drug in interstate commerce and deliver it on112

What did FDA ask the company to do?

In the letter’s own words:

FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1

Has FDA warned the seller I use?

Type a seller’s name or website. The search runs over all 164 letters in this database.

Seller check164 letters
Letters found—
Latest—

How many GLP-1 letters has FDA sent?

70 letters in this database are of the same kind as this one, websites selling drugs that FDA considers unapproved and misbranded. 151 of the 164 letters name semaglutide. The chart counts letters by the quarter of their date; the quarter of this letter is marked.

Letters by quarter2023–2026
Drug named in the letter
Kind of letter
Letters—
Busiest quarter—

Which other sellers got a similar letter?

What does an FDA warning letter mean for someone buying from this seller?

FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.

FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.

A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.

What is the full text of the letter?

This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1

Read the full letter (825 words)

September 9, 2025

Mr. Stern:

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.mystarthealth.com in August 2025 and has observed that your website offers compounded semaglutide. 1 As described below, your claims concerning your compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.

The following claims concerning your compounded semaglutide products appear on your website:

  • “Generic Ozempic”
  • “Save with generics that offer the same active ingredients and results.”

Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].

The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations. 2

For the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].

As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.

You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.

Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.

If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.

All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.

Sincerely,

/s/

George Tidmarsh, M.D., Ph.D. Director

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

1 The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and/or because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.

2 Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.

Content current as of:

09/16/2025

Regulated Product(s)

Drugs

Sources

  1. FDA. Warning letter to Matthew Stern, CEO MyStart Health LLC., September 9, 2025 (MARCS-CMS 714755). fda.gov
  2. FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
  3. FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider